BSX Sheds “Non-Strategic” Businesses for $425M

Xconomy Boston — 

As part of a previously announced restructuring effort, Natick, MA-based Boston Scientific (NYSE: BSX) has agreed to sell two of its businesses to private equity firm Avista Capital Partners for $425 million in cash. With this deal, which is expected to close in the first quarter of next year, “We now have under agreement the divestitures of all five non-strategic businesses we had previously identified for sale,” said Boston Scientific president and CEO Jim Tobin in a statement.